Keymed Biosciences (SEHK:2162) Stock Questions Whether New Profit Can Last

Keymed Biosciences stock has cooled in recent weeks, with the share price down about 10.6% over the past month even after moving into the black over the last year. Today's earnings story is all about profit, not hype. Basic earnings per share for the first half of 2026 came in at ¥4.29, flipping from losses in 2025, and trailing twelve month earnings now support a P/E of 25.4x.

The market is treating that P/E as a question mark. The key issue now is whether investors see this new profitability as durable or as a temporary spike in an expensive biotech stock.

Love Keymed Biosciences finally moving into profit but unsure about paying a 25.4x P/E for a biotech stock where earnings durability is still unclear? Check out our 291 resilient stocks with low risk scores that combines earnings support with lower perceived risk.

H1 2026 Earnings Summary

• Revenue (H1 2026 vs. H1 2025): ¥617.068 million vs. ¥498.752 million (change reflects higher reported revenue year on year)
• Net Income / Loss (H1 2026 vs. H1 2025): Net income of ¥1,217.447 million vs. a loss of ¥78.843 million (shift to profit from loss)
• Basic EPS (H1 2026 vs. H1 2025): ¥4.29 per share vs. a loss of ¥0.298288 per share (swing from loss per share to earnings per share)
• R&D Pipeline Scale (TTM to H1 2026 vs. TTM to H1 2025): 12 products in Phase I, 9 in Phase II, 6 in Phase III, and 1 in pre-registration in the prior trailing period, with current trailing figures not disclosed for comparison (pipeline breadth remains an important driver for Keymed Biosciences)

Prefer clean visual charts instead of scrolling through another page of raw earnings numbers and biotech pipeline tables? See Keymed Biosciences' full financial picture, including a clear view of its valuation, in our company report for Keymed Biosciences.

Profit Turning Point Supports Keymed Bull Story

For investors focused on pipeline breadth and external validation, Keymed Biosciences now has earnings momentum to match the story. Revenue of ¥617.068 million for H1 2026 sits alongside a clear swing to net profit of ¥1,217.447 million and basic EPS of ¥4.29 per share, compared with losses a year ago. That shift gives the BEL512 Phase II success more financial backing. Profitability combined with a late stage partnered asset heading toward Phase III helps the multi asset, partnership focused narrative look more grounded in the current numbers.

Share Pullback Keeps Execution Risks In View

The share price has fallen about 10.6% over the past month even as earnings moved into profit, which indicates that investors are not ignoring execution risk. Returns over 90 days are still positive at about 23.8%, so optimism has not disappeared. The AGM plan to expand issuance authority up to 20% of existing share capital highlights ongoing funding needs for BEL512 Phase III and the wider pipeline. The recent profit print softens near term risk perceptions, but dilution and clinical uncertainty remain key watchpoints for Keymed Biosciences.

Compare Keymed Biosciences' sharp swing into profit and 25.4x P/E with how the market is pricing its future, and see whether analysts view this as a sustainable turnaround or a one off spike by checking the consensus price target analysis for Keymed Biosciences.

Stay Ahead With Simply Wall St

If the sharp swing into profit and current 25.4x P/E leave you watching Keymed Biosciences from the sidelines, register for free with Simply Wall St and add it to your Watchlist to track share price against fair value and watch for an entry point that fits your plan. Once you own it, keep your decisions clear with the Portfolio Command Center that filters out noise and highlights only the most important changes to your holdings. For a broader view, tap into crowd insights and different angles on Keymed Biosciences through the Community. This approach may help you identify potential catalysts and risks early while aiming to stay ahead of the market.

Seeking Alternatives Beyond Keymed Biosciences?

Fresh stock ideas can move fast. Some are building quiet breakout momentum while others may be dropping off the radar. Scan these curated lists before the crowd and consider them carefully.

• Target steadier potential by reviewing a curated group of companies with resilient track records using the 291 resilient stocks with low risk scores before prices fully reflect their perceived strength.
• Explore the early breakout phase in AI by checking hand picked future facing businesses highlighted in the 55 AI infrastructure stocks while they are still under the radar for now.
• Position yourself ahead of the crowd by assessing companies with solid financial footing through the list of solid balance sheet and fundamentals stocks (434 results) while the window for attractive entry points still looks open.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com